Intervention
toxicities, prostate cancer, prostate
CANCER PROGRESSION, ADVERSE EVENT, INFLAMMATION, PROSTATE, SECONDARY, PROSTATE CANCER
Both types of capsule were prepared by SCF Pharma, were odorless, and were identical in appearance. Patients were instructed to take the capsules 7.5 weeks on average (range: 4–10 weeks) prior to RP and to continue for 1‐year post‐RP. At each visit, they were given enough capsules for 3 months by the hospital pharmacist and were instructed to return those not taken since the last visit. No major toxicities were observed for both arms. Adverse events have recently been published in another secondary analysis (quality of life outcomes) of the same trial.
These patients were instructed to take six capsules of 625 mg of fish oil (each containing 500 mg of MAG‐EPA) per day for a total daily dosage of 3 g of EPA. This intervention was chosen based on our previous studies in men with low‐risk prostate cancer which showed that a higher EPA level in prostate tissue, but not DHA, was related to a lower cancer progression risk.
This group had to take six capsules of 625 mg of high oleic acid sunflower oil (mainly n‐9, with no n‐3, and only a trace of n‐6), a biologically neutral oil on inflammation, for a total daily dose of 3.75 g of HOSO.